Your browser doesn't support javascript.
loading
CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
Otsuka, Tomoyuki; Nishida, Sumiyuki; Shibahara, Takayuki; Temizoz, Burcu; Hamaguchi, Masanari; Shiroyama, Takayuki; Kimura, Keiko; Miyake, Kotaro; Hirata, Haruhiko; Mizuno, Yumiko; Yagita, Mayu; Manabe, Yusuke; Kuroda, Etsushi; Takeda, Yoshito; Kida, Hiroshi; Ishii, Ken J; Kumanogoh, Atsushi.
Affiliation
  • Otsuka T; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Nishida S; Department of Medical Oncology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.
  • Shibahara T; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan. sumiyuki-n@imed3.med.osaka-u.ac.jp.
  • Temizoz B; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Hamaguchi M; Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8, Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan.
  • Shiroyama T; Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8, Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan.
  • Kimura K; Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
  • Miyake K; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-4, Shiraganedai, Minato-ku, Tokyo, 108-8639, Japan.
  • Hirata H; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Mizuno Y; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Yagita M; Department of Medical Innovation, Osaka University Hospital, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Manabe Y; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Kuroda E; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Takeda Y; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Kida H; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Ishii KJ; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  • Kumanogoh A; Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8, Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan.
BMC Cancer ; 22(1): 744, 2022 Jul 07.
Article in En | MEDLINE | ID: mdl-35799134
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Language: En Journal: BMC Cancer Year: 2022 Type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Language: En Journal: BMC Cancer Year: 2022 Type: Article Affiliation country: Japan